Mitchell C. Posner to Adenocarcinoma
This is a "connection" page, showing publications Mitchell C. Posner has written about Adenocarcinoma.
Connection Strength
4.142
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
Score: 0.398
-
Transhiatal Esophagectomy for Esophageal Cancer. J Laparoendosc Adv Surg Tech A. 2016 Oct; 26(10):752-756.
Score: 0.323
-
Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol. 2016 06; 23(6):1956-62.
Score: 0.310
-
More harm than good? Ann Surg Oncol. 2014 Sep; 21(9):2817-9.
Score: 0.280
-
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012 Feb; 19(2):384-91.
Score: 0.227
-
Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol. 2010 Aug 14; 16(30):3804-10.
Score: 0.213
-
Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? Lancet Oncol. 2010 May; 11(5):404-5.
Score: 0.208
-
The staging of gastric cancer: nothing novel but perhaps better. Ann Surg Oncol. 2003 Nov; 10(9):1005-6.
Score: 0.133
-
Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
Score: 0.126
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.121
-
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Ann Surg Oncol. 2021 Aug; 28(8):4433-4443.
Score: 0.110
-
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
Score: 0.109
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.103
-
Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer. 2020 01 15; 126(2):281-292.
Score: 0.101
-
Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am. 1998 Jul-Aug; 4(4):237-46.
Score: 0.092
-
Role of nutrition support during induction chemoradiation therapy in esophageal cancer. JPEN J Parenter Enteral Nutr. 1998 Jan-Feb; 22(1):18-21.
Score: 0.089
-
Doubling of 30-Day Mortality by 90 Days After Esophagectomy: A Critical Measure of Outcomes for Quality Improvement. Ann Surg. 2016 Feb; 263(2):286-91.
Score: 0.078
-
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA. 2015 Oct 06; 314(13):1346-55.
Score: 0.076
-
Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg. 2014 Jan; 149(1):18-25.
Score: 0.067
-
National assessment of margin status as a quality indicator after pancreatic cancer surgery. Ann Surg Oncol. 2014 Apr; 21(4):1067-74.
Score: 0.067
-
Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience. Am J Clin Oncol. 2013 Dec; 36(6):637-43.
Score: 0.067
-
What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. Surgery. 2013 Nov; 154(5):1100-9.
Score: 0.066
-
Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg. 2013 Aug; 217(2):347-57.e1.
Score: 0.064
-
Prospective clinical trial of diagnostic peritoneal lavage to detect positive peritoneal cytology in patients with gastric cancer. J Surg Oncol. 2013 Jun; 107(8):794-8.
Score: 0.064
-
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug; 20(8):2787-95.
Score: 0.063
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
Score: 0.063
-
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. Am J Clin Oncol. 1990 Oct; 13(5):455-8.
Score: 0.054
-
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011 Feb; 18(2):337-44.
Score: 0.053
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.053
-
Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience. Am J Gastroenterol. 2009 Nov; 104(11):2684-92.
Score: 0.050
-
Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol. 2008 Feb; 6(2):159-64.
Score: 0.044
-
Presence of distal intramural spread after preoperative combined-modality therapy for adenocarcinoma of the rectum: what is now the appropriate distal resection margin? Surgery. 2005 Oct; 138(4):658-63; discussion 663-4.
Score: 0.038
-
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005 Apr 15; 65(8):3146-54.
Score: 0.037
-
Dual induction of the Epo-Egr-TNF-alpha- plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay. Am Surg. 2003 Jan; 69(1):24-7.
Score: 0.031
-
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. Arch Surg. 2001 Jul; 136(7):737-42; discussion 743.
Score: 0.028
-
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7.
Score: 0.023
-
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 01; 8(1):37-48.
Score: 0.022
-
Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol. 1995 Aug; 18(4):300-2.
Score: 0.019
-
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993 May; 128(5):559-64.
Score: 0.016
-
Efficacy of multimodality therapy in gastric adenocarcinoma. Semin Surg Oncol. 1993 Jan-Feb; 9(1):19-26.
Score: 0.016
-
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
Score: 0.016
-
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
Score: 0.008
-
NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. 2000 Dec 15; 60(24):6958-63.
Score: 0.007
-
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-89-S19-92.
Score: 0.006
-
Peripheral athero-embolism from the aorta complicating transhiatal esophagectomy. Am Surg. 1994 Aug; 60(8):634-7.
Score: 0.004